UPCC 07224 A Platform Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel inhibitors of active, GTP-bound RAS (RAS[ON]), in combination with other anticancer therapies in patients with gastrointestinal solid tumors.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
14 Aug 2024.
Study ID: 856103
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
